PLA-Inhibitors (stoPLA): New class of NSAIDs for oral and transdermal pain treatment

Phospholipase A2 (PLA2) designates a large and diverse

group of enzymes that cleave phospholipids at the sn-2- position. This metabolic step is instrumental in a variety of pathogenic processes causing pain, fever and inflammation. Presently glucocortidoids are used for inhibition of PLA2. Unfortunately, glucocortidoids have serious side effects which limit their use as medication for pain treatment. stoPLA is a new class of heteroaryl-substituted acetone derivatives for the effective inhibition of PLA2, especially of cytosolic PLA2. These compounds effectively interact with the synthesis of prostaglandins and leukotrienes and reduce inflammatory processes. The new heteroarylsubstituted acetone derivatives have also an excellent solubility profile and are stable against metabolic inactivation through ketogroup reduction.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Cooling down solar cells, naturally

Photovoltaics are more efficient when they operate at lower temperatures, which can be achieved in solar farms that space out arrays and use the wind to their advantage. A bright,…

Strongest Arctic cyclone on record led to surprising loss of sea ice

A warming climate is causing a decline in sea ice in the Arctic Ocean, where loss of sea ice has important ecological, economic and climate impacts. On top of this…

Tuberculosis and COVID-19 lung lesions

… revealed by high-resolution three-dimensional imaging. Insights that are not possible with conventional two-dimensional platforms include characterization of obliterated airways in tuberculosis and hemorrhage from ruptured blood vessels in COVID-19…

Partners & Sponsors